ALZN
HEALTHCAREAlzamend Neuro Inc
Live · NASDAQ · May 8, Close
What's Moving ALZN Today?
No stock-specific AI insight has been generated for ALZN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.10
Fundamentals
Trading
ALZN News
14 articles- Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General HospitalYahoo Finance·Apr 7, 2026
- Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain RegionsYahoo Finance·Mar 26, 2026
- Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General HospitalYahoo Finance·Mar 16, 2026
- Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Jan 26, 2026
- EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?Yahoo Finance·Nov 20, 2025
- Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General HospitalYahoo Finance·Nov 19, 2025
- EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy ParticipantsYahoo Finance·Nov 19, 2025
- Alzamend Neuro to Present at the 2025 Military Health System Research SymposiumYahoo Finance·Jul 28, 2025
- Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical ProgramsYahoo Finance·Jul 23, 2025
- Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of ScheduleYahoo Finance·Jun 16, 2025
- Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General HospitalYahoo Finance·May 29, 2025
- Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General HospitalYahoo Finance·May 19, 2025
- Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General HospitalYahoo Finance·May 13, 2025
- EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human ParticipantsYahoo Finance·May 13, 2025
All 14 articles loaded
Price Data
52-Week Range
$1.10
Fundamentals
Trading
About Alzamend Neuro Inc
Alzamend Neuro Inc. is a biotechnology firm committed to developing groundbreaking therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. Utilizing its proprietary drug development platform and a robust intellectual property portfolio, the company aims to meet significant unmet medical needs within the pharmaceutical sector. Through the integration of advanced technologies and strategic collaborations, Alzamend is advancing its therapeutic candidates through clinical trials, with the objective of enhancing patient quality of life. Given its concentrated efforts on critical health issues, Alzamend is well-positioned to make substantial contributions to the field of neurotherapeutics.